Working… Menu
Trial record 42 of 53 for:    "Breast Carcinoma in Situ" | "Hormones"

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00183963
Recruitment Status : Terminated (Insufficient accrual)
First Posted : September 16, 2005
Results First Posted : December 6, 2012
Last Update Posted : May 22, 2014
Information provided by (Responsible Party):
University of Southern California

Brief Summary:

The subjects in this trial have been diagnosed as having a pre-cancerous disease of the breast called ductal carcinoma in situ (DCIS). This condition is associated with the development of breast cancer in up to 50% of cases.

The subjects are being asked to participate in this research study. They are being offered voluntary admission to this study to test the effects of a new investigational drug called Fulvestrant (Faslodex). This drug is approved by the United States Food and Drug Administration (FDA) for the treatment of advanced breast cancer but has not been approved for the treatment of DCIS. However, the FDA has given permission for the drug to be tested in this study. The purpose of this study is to find out if Fulvestrant has any effect on the subject's precancerous changes by comparing samples taken before and after receiving Fulvestrant.

Condition or disease Intervention/treatment Phase
Breast Carcinoma Drug: Tamoxifen Drug: Fulvestrant Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
Study Start Date : August 2006
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Fulvestrant

Arm Intervention/treatment
No Intervention: 1
Active Comparator: 2
Tamoxifen 20 mg
Drug: Tamoxifen

Active Comparator: 3
Fulvestrant 250mg
Drug: Fulvestrant

Active Comparator: 4
Fulvestrant 500mg IM
Drug: Fulvestrant
500 mg IM

Primary Outcome Measures :
  1. Number of Participants With Molecular Changes in Markers of Cell Proliferation and Apoptosis Associated With Treatment [ Time Frame: 6 months after treatment of last patient enrolled ]
    Molecular measures of effect will be measured in tissue obtained at baseline biopsy (paraffin specimen) and on surgical specimen obtained at end of 3 weeks of treatment.

Secondary Outcome Measures :
  1. Number of Participants With Changes in Mammographic Density [ Time Frame: 6 months after treatment of last patient enrolled ]
    The mammograms will be scanned and a validated computer based threshold method will be used to determine the mammographic densities.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal women with newly diagnosed DCIS. Women will be considered to be in menopause if they fall into one of the following groups:

    • Age > 60
    • Age > 45 with amenorrhea > 1 year with intact uterus
    • Status post bilateral oophorectomies
    • FSH/estradiol levels in postmenopausal range for the institution
  • DCIS must have been diagnosed with a minimally invasive biopsy technique, such as a vacuum-assisted large core tool (Mammotome) or an equivalent method.
  • There must be available tissue from the diagnostic biopsy to perform molecular markers.
  • Baseline mammogram within 8 weeks of study entry.
  • Serum creatinine less than or equal to 2.0 mg/dl.
  • Total bilirubin less than or equal to 2.0 upper limit of normal (ULN), transaminases (SGOT and/or SGPT) and alkaline phosphatase may be up to 2.5 x institutional upper limit of normal (ULN), AGC greater than or equal to 1500, platelets greater than or equal to 100,000, Hemoglobin greater than or equal to 8.0 g/dl
  • Peripheral neuropathy grade 0-1.
  • No prior therapy for DCIS.
  • SWOG performance status of less than or equal to 1
  • All patients must provide informed written consent

Exclusion Criteria:

  • Prior hormonal therapy (antiestrogens, estrogen, SERM's, progestins, or aromatase inhibitors) within 6 months of study entry.
  • Underlying medical, psychiatric or social conditions that would preclude patient from receiving treatment.
  • History of DVT or Pulmonary Embolism

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00183963

Layout table for location information
United States, California
Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Sponsors and Collaborators
University of Southern California
Layout table for investigator information
Principal Investigator: Dennis Holmes University of Southern California

Layout table for additonal information
Responsible Party: University of Southern California Identifier: NCT00183963     History of Changes
Other Study ID Numbers: 1B-03-7
First Posted: September 16, 2005    Key Record Dates
Results First Posted: December 6, 2012
Last Update Posted: May 22, 2014
Last Verified: May 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Carcinoma In Situ
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Breast Neoplasms
Carcinoma in Situ
Carcinoma, Ductal
Carcinoma, Intraductal, Noninfiltrating
Carcinoma, Ductal, Breast
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplasms, Ductal, Lobular, and Medullary
Estrogen Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents
Estrogen Receptor Antagonists